IMTX News and Press, Immatics N.V. From 03/21/24

Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median duration of response not reached at median follow-up of 14.4 months; IMA203 was well tolerated Registration-enabling randomized Phase 2/3...

Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...

2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...

2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...

2024-02-21 09:10:00 ET February 21, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, AI, Tech and Cybersecurity sectors. The newest biotech companies work with T-cel...

2024-02-15 09:15:00 ET February 15, 2024 Investorideas.com , a global investor news source covering biotech and pharma stocks issues a sector snapshot on cancer immunotherapy featuring Oncolytics Biotech Inc. ( NASDAQ: ONCY ) (TSX: ONC ), a clinical-stage immunotherapeutics comp...

2024-02-03 07:56:11 ET Summary Immatics is a significant player in T-cell redirecting cancer immunotherapies, with a clinical-stage pipeline showing promising interim results. The company has formed strategic partnerships with Moderna and Bristol Myers Squibb, validating its scien...

2024-01-19 20:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-18 03:25:45 ET More on Immatics Seeking Alpha’s Quant Rating on Immatics Historical earnings data for Immatics Financial information for Immatics For further details see: Immatics prices upsized stock offering to raise $175 million

Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of an und...